Mallinckrodt plc
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Mallinckrodt plc Mallinckrodt plc is a global specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceuticals, active pharmaceutical ingredients, and imaging agents. Founded in 1867 and headquartered in Dublin, Ireland, with operational headquarters in the United States including locations in Hazelwood, Missouri, Bedminster, New Jersey, and Staines-upon-Thames, United Kingdom, the company operates primarily in North America, Europe, Middle East, Africa, and other international markets. Its Specialty Brands segment focuses on therapies for autoimmune and rare diseases across neurology, rheumatology, nephrology, pulmonology, ophthalmology, immunology, urology, hepatology, orthopedics, and critical care; immunotherapy and neonatal respiratory critical care; analgesics; gastrointestinal products; and hemostasis products including extracorporeal photopheresis via Therakos; while the Specialty Generics segment provides specialty generic drugs such as hydrocodone- and oxycodone-containing tablets, other controlled substances for pain management, attention-deficit/hyperactivity disorder medications, addiction treatments, buprenorphine/naloxone (Suboxone), codeine, dextroamphetamine, fentanyl citrate, hydromorphone (Dilaudid), methadone (Methadose), methylphenidate (Ritalin, Concerta), naloxone (Narcan), naltrexone (Revia, Vivitrol), pethidine (Demerol), sufentanil citrate, and various compounded medications with acetaminophen or ibuprofen; medical imaging products encompass contrast media like Optiray (ioversol) for CT scans and Optimark (gadoversetamide) for MRI, alongside radiopharmaceuticals. Key branded products include Acthar Gel (repository corticotropin injection) for infantile spasms, multiple sclerosis exacerbations, and orphan indications; Terlivaz (terlipressin); Ofirmev (IV acetaminophen); Xartemis XR (oxycodone-acetaminophen extended-release); and Exalgo (hydromorphone extended-release). In a transformative strategic shift, Mallinckrodt completed a merger with Endo, Inc. on August 1, 2025, creating a scaled diversified therapeutics leader valued at $6.7 billion, with Mallinckrodt shareholders owning 50.1% pro forma; the combined entity subsequently spun off its generic pharmaceuticals and Endo's sterile injectables into Par Health as a standalone U.S.-advantaged manufacturer, while rebranding the remaining specialty branded business as Keenova Therapeutics in November 2025 to target rare, stigmatized, and unaddressed conditions. Prior to the merger, the company emerged from its second Chapter 11 bankruptcy restructuring on November 14, 2023, reducing funded debt by $1.9 billion, enhancing liquidity, and appointing new board members including David Stetson and Jon Zinman; it also secured FDA approvals for generics like lisdexamfetamine dimesylate capsules (Vyvanse generic), launched delivery innovations for Acthar Gel, and advanced Terlivaz adoption. These changes position the former Mallinckrodt businesses with improved financial flexibility, vertical integration in U.S. manufacturing, and focused portfolios serving hospitals, wholesalers, retail chains, physicians, imaging centers, and patients with severe conditions.
Mallinckrodt plc (MNKTQ) Q4 2025 Earnings Call Transcript
Comparing Mallinckrodt (OTCMKTS:MNKKQ) & NanoViricides (NYSE:NNVC)
Mallinckrodt plc (MNKTQ) Q3 2025 Earnings Call Transcript
Mallinckrodt, Endo Complete Merger to Create Global, Scaled, Diversified Therapeutics Leader
Mallinckrodt plc to Report Earnings Results for Second Quarter 2025
Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc.
Mallinckrodt and Endo Shareholders Approve Combination to Create a Global, Scaled, Diversified Pharmaceuticals Leader
Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company
Mallinckrodt and Endo Announce Significant Progress in Proposed Merger
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Mallinckrodt Pharmaceuticals and Endo announce $6.7B merger
Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm
Mallinckrodt and Endo plan merger as they look to recover from opioid litigation
Mallinckrodt and Endo to Combine to Create a Global, Scaled, Diversified Pharmaceuticals Leader
Drugmakers Mallinckrodt, Endo in talks to merge, Bloomberg News reports
Mallinckrodt plc Reschedules Release of Fourth Quarter and Fiscal Year 2024 Financial Results to Thursday, March 13, 2025
Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Mallinckrodt Securities Litigation
Mallinckrodt Completes Divestiture of Therakos® Business
Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting